# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, presented a poster titled...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biora Therapeutics (NASDAQ:BIOR) with a Buy and maintains $15 pr...
Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(...
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it w...
Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024S...